Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerry Oster

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Limitations of fentanyl/oxycodone database analysisGerry Oster
European Journal of Pain (London, England)|May 6, 2008
Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain?John Edelsberg, Gerry Oster
Archives of Internal Medicine|December 10, 2003
Clinical relevance of bleeding indexGerry Oster, Montserrat Vera
The American Journal of Managed Care|November 4, 2014
Is all "skin in the game" fair game? The problem with "non-preferred" genericsGerry Oster, A Mark Fendrick
Drugs in Context|September 1, 2020
Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United StatesArpita Nag, Rebecca Bornheimer, Gerry Oster
Clinical Therapeutics|December 3, 2013
Economic burden of adverse events in patients with metastatic renal cell carcinomaMay Hagiwara, Rohit Borker, Gerry Oster
The Journal of Infectious Diseases|May 31, 2022
Cost-Effectiveness of Adult Universal Hepatitis B VaccinationGerry Oster, Rebecca Bornheimer, Kevin Ottino
Diabetes Care|September 28, 2002
Response to Lamotte et Al. "A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients."John Edelsberg, Derek Weycker, Gerry Oster
The Journal of Rheumatology|November 18, 2011
Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritisKaleb Michaud, Montserrat Vera-Llonch, Gerry Oster
Journal of Medical Economics|September 6, 2013
Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinomaMay Hagiwara, Michelle D Hackshaw, Gerry Oster
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Limitations of fentanyl/oxycodone database analysisGerry Oster
European Journal of Pain (London, England)|May 6, 2008
Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain?John Edelsberg, Gerry Oster
Archives of Internal Medicine|December 10, 2003
Clinical relevance of bleeding indexGerry Oster, Montserrat Vera
The American Journal of Managed Care|November 4, 2014
Is all "skin in the game" fair game? The problem with "non-preferred" genericsGerry Oster, A Mark Fendrick
Drugs in Context|September 1, 2020
Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United StatesArpita Nag, Rebecca Bornheimer, Gerry Oster
Clinical Therapeutics|December 3, 2013
Economic burden of adverse events in patients with metastatic renal cell carcinomaMay Hagiwara, Rohit Borker, Gerry Oster
The Journal of Infectious Diseases|May 31, 2022
Cost-Effectiveness of Adult Universal Hepatitis B VaccinationGerry Oster, Rebecca Bornheimer, Kevin Ottino
Diabetes Care|September 28, 2002
Response to Lamotte et Al. "A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients."John Edelsberg, Derek Weycker, Gerry Oster
The Journal of Rheumatology|November 18, 2011
Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritisKaleb Michaud, Montserrat Vera-Llonch, Gerry Oster
Journal of Medical Economics|September 6, 2013
Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinomaMay Hagiwara, Michelle D Hackshaw, Gerry Oster
Pageof 12